Abstract
HER-2, or Human Epidermal Growth Factor Receptor-2, is a constituent of the epidermal growth factor receptor family, possessing tyrosine kinase properties. Its over-expression has been correlated with breast cancer. On the other hand, the pharmacological potential of Momordica charantia has been attributed to the phytocompounds. Herein, the inhibiting potential of phytocompounds from M. charantia against HER-2 was investigated using computational approaches. Maestro Schrodinger software (2021 v 12.1) was used to perform molecular docking, molecular mechanics generalized Born surface area (MM/GBSA), and pharmacokinetics prediction of a hundred phytocompounds from M. charantia against HER-2. The result revealed that among the phytocompounds, ve (5) showed promising inhibitory potential comparable to the standard drug, Getinib. The MM/GBSA result showed that Rutin, Quercetin, Isoquerrcitrin, Folic Acid, and riboavin formed a more stable complex with HER-2 than Getinib. The pharmacokinetics prole of the hit compounds showed that the hit compounds except riboavin violated two or more of Lipinski's rule of ve. In conclusion, the bioactive compounds found in M. charantia could potentially act as primary candidates for the creation of effective inhibitors targeting HER-2 in the treatment of breast cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
